Nadofaragene firadenovec
Adstiladrin (nadofaragene firadenovec) is a gene pharmaceutical. Nadofaragene firadenovec was first approved as Adstiladrin on 2022-12-16.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Adstiladrin
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Nadofaragene firadenovec
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Adstiladrin | nadofaragene firadenovec-vncg | Ferring Pharmaceuticals | N-125700 RX | 2022-12-16 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adstiladrin | Biologic Licensing Application | 2024-10-30 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
nadofaragene firadenovec, Adstiladrin, Ferring Pharmaceuticals A/S | |||
| 2034-12-16 | Reference product excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | 1 | 5 | 6 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 1 | 2 | 1 | 1 | 6 |
| Latent tuberculosis | D055985 | — | Z22.7 | — | — | — | 1 | 4 | 5 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-muscle invasive bladder neoplasms | D000093284 | — | — | — | — | 2 | — | 1 | 3 |
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | 1 | — | — | 2 |
| Malignant mesothelioma | D000086002 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 2 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 1 | — | — | — | 1 |
| Lymphomatoid granulomatosis | D008230 | — | C83.8 | — | 1 | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 1 | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 1 | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | — | 1 |
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | 1 | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | — | O98.7 | — | — | — | — | 1 | 1 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | — | — | — | 1 | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 1 | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 1 | 1 |
| Exocrine pancreatic insufficiency | D010188 | — | K86.81 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nadofaragene firadenovec |
| INN | nadofaragene firadenovec |
| Description | Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer. It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy.
|
| Classification | Gene |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990041 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB17381 |
| UNII ID | 0OOS09O1FH (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 281 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
296 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use